Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study to Investigate the Efficacy and Safety of QGE031 in Adolescent Patients With Chronic Spontaneous Urticaria (CSU)

Phase 2

Completed

Conditions: Chronic Spontaneous Urticaria

Interventions: Drug: Ligelizumab
Drug: Placebo

First Posted Date: 2018-02-19

Last Posted Date: 2022-04-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 49

Registration Number: NCT03437278

Locations: 🇹🇷
Novartis Investigative Site, Aydin, Turkey

VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib

Phase 1

Terminated

Conditions: Chronic Lymphocytic Leukemia (CLL)

Interventions: Drug: VAY736
Drug: ibrutinib

First Posted Date: 2018-01-17

Last Posted Date: 2023-11-14

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 39

Registration Number: NCT03400176

Locations: 🇺🇸
University of California San Diego - Moores Cancer Center, La Jolla, California, United States
🇺🇸
David Geffen School of Medicine at UCLA David Geffen School of Med, Los Angeles, California, United States
🇺🇸
Ohio State Comprehensive Cancer Center/James Cancer Hospital Ohio State University, Columbus, Ohio, United States

and more 2 locations

Efficacy and Safety of MAA868 in Patients With Atrial Fibrillation

Phase 2

Withdrawn

Conditions: Atrial Fibrillation

Interventions: Drug: MAA868
Drug: Apixaban

First Posted Date: 2018-01-12

Last Posted Date: 2020-10-08

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT03398434

Prevention of Thromboembolic Events in Total Knee Replacement Patients

Phase 2

Withdrawn

Conditions: Thrombotic Disorders

Interventions: Drug: MAA868
Drug: Enoxaparin

First Posted Date: 2018-01-08

Last Posted Date: 2020-10-08

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT03393481

Patient Reported Outcomes inVestigation Following Initiation of Drug Therapy With Entresto (Sacubitril/Valsartan) in Heart Failure

Completed

Conditions: Heart Failure, Systolic

Interventions: Drug: Sacubitril/Valsartan

First Posted Date: 2017-12-29

Last Posted Date: 2019-12-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 402

Registration Number: NCT03387163

Locations: 🇺🇸
Novartis Investigative Site, New York, New York, United States

Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD

Phase 3

Completed

Conditions: Neovascular Age-related Macular Degeneration

Interventions: Drug: Brolucizumab 6 mg
Drug: Aflibercept 2 mg

First Posted Date: 2017-12-29

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 151

Registration Number: NCT03386474

Locations: 🇵🇷
Novartis Investigative Site, San Juan, Puerto Rico

Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia.

Phase 3

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Midostaurin
Drug: Cytarabine

First Posted Date: 2017-12-20

Last Posted Date: 2024-02-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 301

Registration Number: NCT03379727

Locations: 🇸🇪
Novartis Investigative Site, Uppsala, Sweden

A Randomized Study to Evaluate the Effect of Reminder Notifications and Motivational/Adaptive Messaging on Treatment Adherence

Phase 3

Terminated

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Combination Product: Concept2 inhaler with patient application
Combination Product: Concept2 inhaler

First Posted Date: 2017-12-20

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 7

Registration Number: NCT03379233

Locations: 🇳🇱
Novartis Investigative Site, Zutphen, Netherlands

LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Urinary Tract Infection (cUTI)

Phase 2

Withdrawn

Conditions: Complicated Urinary Tract Infections

Interventions: Drug: Standard of care therapy
Drug: LYS228

First Posted Date: 2017-12-19

Last Posted Date: 2018-10-26

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT03377426

Locations: 🇬🇷
Novartis Investigative Site, Athens, Greece

A First-in-human, Proof of Concept Study of CPK850 in Patients With RLBP1 Retinitis Pigmentosa

Phase 1

Active, not recruiting

Conditions: Retinitis Pigmentosa

Interventions: Biological: CPK850

First Posted Date: 2017-12-15

Last Posted Date: 2025-01-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 12

Registration Number: NCT03374657

Locations: 🇸🇪
Novartis Investigative Site, Stockholm, Sweden

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy